Equities Analysts Issue Forecasts for KYTX Q3 Earnings

Key Points

• William Blair analysts project that Kyverna Therapeutics will report a Q3 2025 earnings per share (EPS) of ($0.99), while the full-year earnings forecast is ($3.29) per share.
• HC Wainwright upgraded Kyverna Therapeutics from a "neutral" to a "buy" rating, increasing the price target from $4.00 to $5.00, with an average price target of $15.60 from analysts.
• The company's stock has a market capitalization of approximately $154.84 million, with a share price currently around $3.58, showing a 12-month trading range between $1.78 and $8.78.

Kyverna Therapeutics, Inc. (NASDAQ:KYTX - Free Report) - Equities research analysts at William Blair issued their Q3 2025 EPS estimates for Kyverna Therapeutics in a report issued on Wednesday, August 20th. William Blair analyst S. Corwin forecasts that the company will post earnings of ($0.99) per share for the quarter. William Blair has a "Outperform" rating on the stock. The consensus estimate for Kyverna Therapeutics' current full-year earnings is ($3.29) per share. William Blair also issued estimates for Kyverna Therapeutics' Q4 2025 earnings at ($1.04) EPS, FY2025 earnings at ($4.04) EPS, FY2026 earnings at ($4.21) EPS and FY2027 earnings at ($3.54) EPS.

Kyverna Therapeutics (NASDAQ:KYTX - Get Free Report) last announced its quarterly earnings results on Tuesday, August 12th. The company reported ($0.97) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.00) by $0.03.

Separately, HC Wainwright raised shares of Kyverna Therapeutics from a "neutral" rating to a "buy" rating and increased their price objective for the stock from $4.00 to $5.00 in a research note on Tuesday, May 27th. One research analyst has rated the stock with a Strong Buy rating and six have given a Buy rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Buy" and an average price target of $15.60.

Kyverna Therapeutics Price Performance

Kyverna Therapeutics stock traded down $0.04 during midday trading on Friday, reaching $3.74. 96,531 shares of the company traded hands, compared to its average volume of 367,459. The firm has a market capitalization of $161.76 million, a price-to-earnings ratio of -1.01 and a beta of 3.05. The business has a 50 day moving average of $3.49 and a two-hundred day moving average of $2.81. Kyverna Therapeutics has a 12 month low of $1.78 and a 12 month high of $8.28.

Hedge Funds Weigh In On Kyverna Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Phoenix Wealth Advisors acquired a new stake in Kyverna Therapeutics in the second quarter valued at approximately $32,000. Catalyst Funds Management Pty Ltd acquired a new position in shares of Kyverna Therapeutics in the 2nd quarter valued at $37,000. Squarepoint Ops LLC acquired a new position in Kyverna Therapeutics in the 4th quarter valued at $43,000. Qube Research & Technologies Ltd acquired a new position in Kyverna Therapeutics in the 2nd quarter valued at $43,000. Finally, Corton Capital Inc. acquired a new position in shares of Kyverna Therapeutics during the 4th quarter worth $45,000. 18.08% of the stock is currently owned by institutional investors and hedge funds.

About Kyverna Therapeutics

Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.